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Abstract: Mortality rates due to invasive candidiasis remain unacceptably high, in part because
the poor sensitivity and slow turn-around time of cultures delay the initiation of antifungal
treatment. β-D-glucan (Fungitell) and polymerase chain reaction (PCR)-based (T2Candida) assays
are FDA-approved adjuncts to cultures for diagnosing invasive candidiasis, but their clinical
roles are unclear. We propose a Bayesian framework for interpreting non-culture test results
and developing rational patient management strategies, which considers test performance and
types of invasive candidiasis that are most common in various patient populations. β-D-glucan
sensitivity/specificity for candidemia and intra-abdominal candidiasis is ~80%/80% and ~60%/75%,
respectively. In settings with 1%–10% likelihood of candidemia, anticipated β-D-glucan positive and
negative predictive values are ~4%–31% and ě97%, respectively. Corresponding values in settings
with 3%–30% likelihood of intra-abdominal candidiasis are ~7%–51% and ~78%–98%. β-D-glucan
is predicted to be useful in guiding antifungal treatment for wide ranges of populations at-risk for
candidemia (incidence ~5%–40%) or intra-abdominal candidiasis (~7%–20%). Validated PCR-based
assays should broaden windows to include populations at lower-risk for candidemia (incidence
ě~2%) and higher-risk for intra-abdominal candidiasis (up to ~40%). In the management of individual
patients, non-culture tests may also have value outside of these windows. The proposals we put forth
are not definitive treatment guidelines, but rather represent starting points for clinical trial design
and debate by the infectious diseases community. The principles presented here will be applicable
to other assays as they enter the clinic, and to existing assays as more data become available from
different populations.
Keywords: invasive candidiasis; candidemia; intra-abdominal candidiasis; β-D-glucan; polymerase
chain reaction (PCR); diagnosis; Bayesian
1. Introduction
Candidemia and other types of invasive candidiasis carry mortality rates of 25%–40% [1]. Prompt
antifungal treatment improves outcomes [2,3], but gold standard diagnostic tests (blood or deep-tissue
site cultures) are ~50% sensitive, have turn-around times of several days, and often turn positive late
in the disease [4]. Deep-tissue cultures are further limited by need for invasive procedures, which
are often contra-indicated due to underlying medical conditions. Poor outcomes and shortcomings
of cultures promote antifungal therapy in the absence of conclusive diagnoses, a practice of unclear
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benefit in many settings that may impact institutional ecology, antifungal resistance and pharmacy
budgets [4,5]. Non-culture diagnostics such as β-D-glucan or polymerase chain reaction (PCR) assays
detect Candida cellular components in blood or serum, rather than viable organisms. Used judiciously
as adjuncts to cultures, these tests can identify more patients with invasive candidiasis, at earlier
disease stages [4]. However, there is uncertainty about the performance of non-culture diagnostics in
routine practice, and their roles in patient management.
In this paper, we present a paradigm for incorporating non-culture tests into antifungal treatment
strategies. In developing these strategies, we review the types of invasive candidiasis, performance
of β-D-glucan and PCR assays, and interpretation of test results among different patient groups.
We describe a Bayesian framework for applying test results to patient management, and suggest
settings in which non-culture diagnostics may be most useful. The proposals we put forth are not
definitive treatment guidelines, but rather starting points for discussions and debate. The principles
presented here will be applicable to other assays as they enter the clinic, and to existing assays as more
data become available from different populations.
2. Invasive Candidiasis in Various Populations
Invasive Candida infections comprise candidemia and deep-seated candidiasis (submucosal
tissue and organ infections), diseases that may occur concurrently or independently. Approximately
50% of primary candidemia results in secondary deep-seated candidiasis due to hematogenous
seeding [4]. Primary deep-seated candidiasis stems from non-hematogenous introduction of Candida
into sterile sites, most commonly the abdominal cavity. Studies suggest that <20% of primary
deep-seated candidiasis is associated with secondary candidemia [6–8]. As detailed below, diagnostic
test performance may differ for candidemia and deep-seated candidiasis. Therefore, it is impossible
to critically assess studies of non-culture tests or interpret results at the bedside without considering
the type of invasive candidiasis that is being diagnosed. We will focus on candidemia and
intra-abdominal candidiasis.
Candidemia and intra-abdominal candidiasis are believed to occur with equal frequency [4,9].
The predominant disease is dictated by the clinical setting. In general, candidemia is a low-incidence
disease among relatively large at-risk populations. Risk factors are non-specific and common in
hospitalized patients, including broad-spectrum antibiotics, intravenous access devices, total parenteral
nutrition, mechanical ventilation, renal insufficiency and replacement therapy, diabetes mellitus,
corticosteroids, neutropenia or neutrophil dysfunction, and Candida colonization [10]. The incidence
of candidemia increases from <1% to ~10% as one moves from any hospitalized patient in whom
blood cultures are collected, to low-risk intensive care unit (ICU) patients or patients undergoing
non-gastrointestinal (GI) surgery [11,12], to more moderate-risk patients who are ICU residents for
ě4 days or who are in septic shock [13,14], to higher-risk ICU patients identified by clinical prediction
rules [13,15,16] (Table 1). In contrast, intra-abdominal candidiasis is a relatively high-incidence disease
among more narrowly-defined populations. While patients often have some of the risks above, the
disease does not occur in the absence of predisposing factors involving the gastrointestinal (GI) tract or
digestive system. Common examples include severe pancreatitis or disruption of GI tract or peritoneal
cavity integrity by disease or medical intervention. The incidence of intra-abdominal candidiasis
increases from ~3% to ě30% as one moves from low-to-moderate risk peritoneal dialysis patients with
peritonitis [17,18], to high-risk patients with severe acute or necrotizing pancreatitis, or recurrent leaks
of the GI tract [8,10,19] (Table 1). In most patients, the predominant type of invasive candidiasis should
be apparent when clinicians order a diagnostic test.
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Table 1. Incidence of invasive candidiasis in various populations.
Risk of IC * Patient Characteristics Type of IC ** Incidence *** References
Low
‚ Any hospitalized patient in whom a blood
culture is collected
‚ Residence in the ICU without further
risk stratification




‚ Peritoneal dialysis with peritonitis Intra-abdominal
candidiasis ~3%–6% [21]
‚ Presence of septic shock
‚ ICU residence for ě4 days
Candidemia ~3%–7% [13,14,16]
Moderate
‚ ICU residence for ě4 days with
additional risk factors for IC Candidemia ~10%–15% [13,16]
High
‚ Severe acute or necrotizing pancreatitis
‚ Recurrent GI track leak requiring surgery
Intra-abdominal
candidiasis ~20%–40% [7,8,19]
IC: Invasive candidiasis; ICU: Intensive care unit; GI: Gastrointestinal; * For descriptive purposes, the follow
definitions of level of risk were used: Low: <3%, Low-to-moderate: 3%–10%, Moderate: 10%–20%, High: >20%;
** The most common types of IC are provided. Among patients with candidemia, ~50% will develop secondary
deep-seated candidiasis. Among patients with intra-abdominal candidiasis, up to 20% may have secondary
candidemia; *** Data are selected from representative publications. Incidence in comparable patient populations
may differ by center. In order to best interpret and utilize non-culture test results, clinicians should be aware of
the approximate incidence of invasive candidiasis in various settings at their centers.
3. Non-Culture Diagnostic Test Performance
Two assays are approved by the U.S. Food and Drug Administration (FDA) as adjuncts to cultures
for the diagnosis of invasive candidiasis. The more widely studied test is a serum β-D-glucan assay
(Fungitell; Associates of Cape Cod, East Falmouth, MA, USA), which is cleared for diagnosing a
variety of invasive fungal infections. The assay does not provide Candida speciation nor distinguish
between Candida, Aspergillus and certain other fungi. In meta-analyses of β-D-glucan studies,
pooled sensitivity and specificity for invasive candidiasis were 75%–80% and 80%, respectively [21,22].
The more recently approved T2Candida assay (T2 Biosystems, Lexington, MA, USA) uses a
self-contained instrument to amplify and detect Candida DNA within whole blood by PCR and
T2 magnetic resonance, respectively. FDA approval was based on data from 1501 control patients
with Candida-negative blood cultures, and 250 contrived blood specimens spiked with C. albicans,
C. glabrata, C. parapsilosis, C. tropicalis or C. krusei at concentrations ranging from 1 to 100 CFU/mL [20].
The overall sensitivity and specificity were 91% and 99%, respectively. The performance of the assay
(in particular, its sensitivity) awaits corroboration, as there are limited published data on whole blood
specimens from patients with invasive candidiasis [20,23]. Nevertheless, the preliminary findings are
in keeping with meta-analysis of Candida PCR studies, in which pooled sensitivity and specificity
for invasive candidiasis were 95% and 92%, respectively [24]. PCR offers potential advantages over
β-D-glucan by performing Candida speciation. β-D-glucan may offer advantages among patients in
whom aspergillosis and other invasive fungal infections are also considerations.
Definitive interpretation of β-D-glucan and PCR studies is complicated by numerous factors,
including heterogeneity in patient and control populations, types of Candida species (or other fungi),
testing schedules, definitions of positive test results, and other aspects of research design and data
analysis. Meta-analyses have included studies with cohort and case-control designs, in which cases
were defined as proven or probable infections and healthy controls were excluded [21,22]. Such
studies may overstate performance by excluding possible disease or difficult-to-interpret cases that are
commonly encountered in practice. Most studies have enrolled patients with hematologic malignancies
or ICU residents. Data are more limited for several important populations at-risk for invasive
candidiasis, including solid organ transplant recipients [25]. Studies suggest that β-D-glucan testing
of lung and liver transplant recipients may be particularly susceptible to false-positive β-D-glucan
results [26,27]. To date, most studies have included a preponderance of patients with candidemia
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rather than non-bloodstream, deep-seated candidiasis. Therefore, sensitivities and specificities cited
above are likely best case scenarios for the diagnosis of candidemia.
The major advantage of non-culture tests over cultures for diagnosing active candidemia may not
be improved sensitivity, but rather shorter turn-around times that facilitate earlier treatment. In fact,
broth-based blood cultures are quite sensitive at recovering viable Candida from the bloodstream,
with median limits of detection of ~1 CFU/mL [28,29]. Isolator blood culture systems may be more
sensitive [30,31]. As such, cultures should be positive during the majority of ongoing Candida
bloodstream infections. If cultures are negative due to extremely low-level candidemia, the extent
to which currently available non-culture tests will make the diagnosis is unclear. Indeed, diagnostic
studies of blood culture-positive invasive candidiasis commonly face a “candidemia paradox”, in which
non-culture tests appear inferior to a gold standard that is accepted to be suboptimal. For diseases other
than candidemia, the biggest clinical impact of a non-culture diagnostic will come from identifying
blood culture-negative, primary or secondary deep-seated candidiasis.
In two recent studies, Fungitell β-D-glucan was 53%–65% sensitive and 73%–78% specific for
diagnosing deep-seated Candida infections, in particular intra-abdominal candidiasis [6,7]. Blood
cultures were only 7%–21% sensitive. Sensitivity and specificity of Candida PCR for deep-seated
candidiasis were 89% and 70%, respectively, in one of the studies [6]. β-D-glucan and PCR identified at
least some cases of deep-seated candidiasis that were missed by blood cultures, likely by detecting
targets released from infected tissues or that persisted within the bloodstream after elimination of viable
cells. In both studies, negative controls were at high-risk for intra-abdominal candidiasis. As such, it is
very difficult to interpret specificity of the tests, as positive results despite negative cultures may have
been false-positives, or true-positives that were missed by cultures. Indeed, uncertainty over how to
interpret non-culture test results at the bedside has limited their widespread use.
4. Interpreting Non-Culture Tests in Various Populations
No matter how sensitive or specific non-culture assays for invasive candidiasis may be, clinicians
must accept a level of uncertainty when interpreting results. By definition, a positive blood culture or
tissue culture obtained in a sterile manner establishes the diagnosis of invasive candidiasis. In contrast,
non-culture tests are Bayesian biomarkers that assign a probability of disease, which is shaped by
the pre-test likelihood, and sensitivity and specificity. Positive and negative predictive values (PPVs,
NPVs) can be calculated for β-D-glucan and a PCR assay such as T2Candida in various clinical settings.
Examples of anticipated post-test probabilities of invasive candidiasis with positive and negative
results for different assays are provided in Table 2.
Table 2. Performance of non-culture tests for invasive candidiasis in various populations.




Post-Test Probability of IC
β-D-Glucan ** PCR *** Ideal Assay ****
Pos. Neg. Pos. Neg. Pos. Neg.
Candidemia
Low 1% 4% <1% 8% <1% 48% <1%
Low-to-moderate 5% 17% 1% 32% <1% 83% <1%
Moderate 10% 31% 3% 50% 1% 91% 1%
Intra-abdominal
candidiasis
Low-to-moderate 5% 11% 3% 12% 1% 83% <1%
Moderate 10% 21% 6% 23% 3% 91% 1%
High 30% 51% 22% 53% 11% 97% 4%
PCR: Polymerase chain reaction; Pos: Positive; IC: Invasive candidiasis; Neg: Negative * Pre-test probability of
invasive candidiasis is approximated from Table 1; ** Sensitivity/specificity for candidemia and intra-abdominal
candidiasis were assumed to be 80%/80% and 60%/75%, respectively; *** Sensitivity/specificity for
candidemia and intra-abdominal candidiasis were assumed to be 90%/90% and 80%/70%, respectively;
**** Sensitivity/specificity for candidemia and intra-abdominal candidiasis were assumed to be 90%/99%
and 90%/99%, respectively.
At low pre-test likelihoods of either disease, PPVs and NPVs are extremely low and extremely
high, respectively. As likelihoods increase, PPVs improve at the expense of NPVs. For candidemia,
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β-D-glucan NPVs remain exceptional (ě97%) in each of the clinical settings; PPV is 31% in the
high-risk ICU setting. The superior sensitivity and specificity of PCR are expected to improve PPVs
for candidemia compared to β-D-glucan, but the impact on NPVs is likely negligible. If T2Candida is
shown to perform as reported in the initial clinical study, PPVs improve further. PPVs and NPVs are
lower for intra-abdominal candidiasis than candidemia at a given pre-test likelihood, due to lower
sensitivities and specificities. β-D-glucan NPV for intra-abdominal candidiasis is strong (ě97%) in
low-risk settings, but values drop to ~80% in higher-risk settings (e.g., severe acute or necrotizing
pancreatitis, high-risk GI surgery). β-D-glucan PPV rises to 51% among the highest-risk patients. The
superior performance of PCR impacts NPVs in the higher-risk settings, but has less impact on PPVs.
There are no data for T2Candida in this setting, but the assay should perform at least as well as PCR.
Table 2 illustrates the Bayesian nature of non-culture diagnostics. The practical challenge is
applying these data to the care of patients. How are non-culture diagnostics most likely to be useful in
guiding management strategies?
5. Integrating Non-Culture Tests into Patient Management Strategies
5.1. Screening for Antifungal Treatment
Since non-culture tests are Bayesian rather than categorical, the interpretation and utilization of
results are left to clinical judgment. Broadly speaking, non-culture diagnostics may be used to screen
populations for invasive candidiasis, or manage individual patients. At the population level, screening
may be incorporated into pre-emptive or prophylactic antifungal strategies, in which treatment is
initiated in response to a positive test result or discontinued in response to negative result, respectively.
These strategies are attractive conceptually, but they have not been validated conclusively [15,32,33].
A key issue to be resolved for prophylaxis strategies will be the impact of antifungal treatment on test
performance. ICUs are attractive settings for interventions based on non-culture screening because
empiric and prophylactic antifungal use is wide-spread, populations at-risk for either candidemia or
intra-abdominal candidiasis can be identified, and periods of greatest risk can be defined. A paradigm
that uses non-culture diagnostics and blood cultures to guide pre-emptive or prophylactic treatment
is presented in Figure 1. The paradigm assumes a two-stage decision-making process in which
non-culture results are available before concurrently-collected blood cultures. Its feasibility in a given
setting will depend upon PPVs and NPVs at each stage.
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Figure 1. Paradigm  for  incorporating non‐culture  tests  into antifungal  treatment strategies against 
invasive candidiasis  (IC). The paradigm can be applied  to pre‐emptive or prophylactic antifungal 
strategies. Treatment decisions are made at  two stages,  in response  to non‐culture  test results and 




Table  3. Windows  in which  non‐culture  tests  are  predicted  to  be  useful  in  guiding  antifungal 
treatment. 
Figure 1. Paradigm for incorporating non-culture tests into antifungal treatment strategies against
invasive candidiasis (IC). The paradigm can be applied to pre-emptive or prophylactic antifungal
strategies. Treatment decisions are made at two stages, in response to non-culture test results and
non-culture results combined with blood cultures, respectively. The viability of the paradigm depends
upon positive and negative predictive values (PPVs and NPVs) at each stage. By applying data from
Table 2, clinical settings in which non-culture test-driven strategies are likely to be useful can be
identified (Table 3).
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Table 3. Windows in which non-culture tests are predicted to be useful in guiding antifungal treatment.
Predominant








β-DG 1 ~5% to 40% *
Low-to-moderate- to
high-risk ICU patients
NPVs are ě~85% at pre-test likelihoods as high as the upper
limits of these ranges, suggesting that an antifungal strategy
would remain viable. Compared to β-D-glucan, a hypothetical
PCR or other ideal assay would broaden the window for
antifungal treatment to include lower-risk patients, including
those in septic shock.
Based on the particulars of a case, clinicians may decide to stop
antifungal treatment if blood cultures are negative despite
positive non-culture test results. With negative blood cultures,
β-D-glucan or PCR PPVs are <15% in all settings with pre-test
likelihood <~15%.
PCR 2 ~2% to 60% * Low- to high-risk ICU
patients, and patients in
septic shock
Ideal assay 3 ~1% to 60% *
IAC
β-DG 4 ~7% to 20%
Patients with severe
pancreatitiis
Compared to β-D-glucan, a hypothetical PCR assay would
broaden the window for antifungal treatment to include high-risk
surgery patients with GI leaks, or high-risk liver transplant
recipients with bile leaks. An ideal assay for intra-abdominal
candidiasis would further broaden the window to include
lower-risk patients.
Using negative blood culture results to justify withholding
pre-emptive treatment or discontinuing prophylaxis among
patients with negative β-D-glucan results may broaden the
window of pre-test likelihoods to ~7%–30%. Otherwise, negative
blood cultures do not significantly impact antifungal strategies.
PCR 5 ~7% to 40%




Ideal assay 3 ~1% to 60%
Peritoneal dialysis patients
with peritonitis, in addition
to groups above
IC: Invasive candidiasis; DSC: Deep-seated candidiasis; IAC: Intra-abdominal candidiasis; β-DG: β-D-glucan;
PCR: Polymerase chain reaction; ICU: Intensive care unit; NPV: Negative predictive value; PPV: Positive
predictive value; GI: Gastrointestinal; † Windows defined by PPV ě15% and NPV ě85%; * In general,
clinical prediction models have identified patients with incidence of candidemia up to ~16% [13,16];
1 Sensitivity/specificity: 80%/80% 2 90%/90% 3 90%/99% 4 60%/75% 5 80%/70%.
PPV and NPV thresholds that justify antifungal treatment are not established. Several studies
suggest that prophylaxis is beneficial in preventing invasive fungal infections in various settings
with baseline rates of disease ě~15% [34–40]. As such, it is reasonable to hypothesize that this
target is the threshold PPV for initiating pre-emptive antifungal treatment, and a threshold NPV to
withhold antifungal treatment is ě~85%. NPVs beneath this threshold may leave too high a post-test
probability of invasive candidiasis for antifungals to be deferred. In order for non-culture screening
to be viable, a positive or negative result must provide marginal value beyond simply knowing the
pre-test likelihood. In other words, do results sufficiently change the probability of invasive candidiasis
such that threshold PPVs and NPVs are achieved? In certain low- and high-risk settings, the answer to
this question is no, and screening with non-culture tests will not be useful.
At very low pre-test likelihoods of either candidemia or intra-abdominal candidiasis, the practical
value of negative test results is negligible. For example, a negative β-D-glucan in a setting that is
low-risk for candidemia is predicted to reduce disease likelihood from ~1%–3% to <1%. At the same
time, a β-D-glucan PPV of ~4%–11% is likely to be too low to justify treatment without a positive
culture or other evidence of disease. At some high-end pre-test likelihood, NPVs become too low to
be useful clinically. The NPV of β-D-glucan among high-risk GI surgery patients (pre-test likelihood
~30%) is only 78%, meaning clinicians must be willing to forego treatment despite a >20% chance that
intra-abdominal candidiasis is present. Likewise, it is not clear that the 51% PPV of β-D-glucan in
these settings has greater practical value than knowing the pre-test likelihood. At some point, the
pre-test likelihood of invasive candidiasis may be sufficient to justify antifungal treatment regardless
of non-culture test results. Indeed, universal prophylaxis is beneficial among groups such as bone
marrow transplant recipients, surgical patients with recurrent GI leaks, and high-risk liver transplant
recipients with bile leaks (ě30% incidence of Candida infection) [7,17].
If data from Table 2 are applied to the paradigm, windows of pre-test likelihoods can be assigned
in which non-culture tests are most likely to be valuable in guiding pre-emptive or prophylactic
treatment (Figure 2). Conclusions that may be drawn from this exercise are summarized in Table 3. The
improved performance of a hypothetical PCR assay over β-D-glucan should expand the populations
for antifungal treatment. PCR is expected to have greatest impact among those at-risk for candidemia,
as a pre-emptive or prophyactic strategy becomes viable for lower-risk ICU patients (e.g., ICU resident
J. Fungi 2016, 2, 10 7 of 11
for ě4 days) and patients in septic shock. PCR is also predicted to extend treatment to patients
at highest-risk for intra-abdominal candidiasis. An ideal non-culture test would diagnose both
candidemia and intra-abdominal candidiasis with sensitivity/specificity of ~90%/99% (in other words,
similar to the performance of T2Candida in preliminary studies of candidemia). A test with this
performance for intra-abdominal candidiasis, rather than 80%/70% sensitivity/specificity suggested
by the PCR literature, would expand the window to include lower-risk populations such as surgical
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of  the window,  the  likely best  strategy  is  to administer universal antifungal prophylaxis. Precise 
Figure 2. Schematic representation of the value of non-culture diagnostic tests in guiding antifungal
treat ent strategies. Data fro Table 2 can be applied to the paradig of Figure 1 to identify the
range of pre-test likelihoods ( indo s) in hich non-culture tests are predicted to be useful. If tests
are perfor ed in settings with very low incidence of invasive candidiasis, PPVs generally are too
low to justify antifungal treatment and NPVs do not add significant marginal value over simply
knowing the pre-test likelihood. As pre-test likelihood increases, improved PPVs hit a threshold at
which pre-emptive treatment is beneficial. NPVs remain sufficiently igh that a tifungal treatment can
b def rred witho t undue pro ability that invasive can idiasis is present. At so e i er r -t st
li li , r, s it t r s l t i t r ilit f i si i i sis is t i
t forego antifungal treatment. The window in hich non-culture tests promote e-emptive treatment
is defined by th pr -test likelihoods associated with threshold PPVs and NPVs (represente by bar
in figure). A supe ior test (r present d in blue) broadens the window compar d to an inferior t st
(represented in red) by improving PPV and/ r NPV, thereby dropping the low-end and/or raisi g
the high-end pre-test lik lihood (a shown by horizontal blue ar ows). A s perior test also has greater
value in screening due to its higher PPV and/or NPV at a given pre-tes likelihood (as shown by sm ll
vertical blue rrow).
t pre-test likelihoods belo the low-end of the window, the likely best management strategy is
to defer testing and not initiate antifungal treatment. At pre-test likelihoods beyond the high-end of the
windo , the likely best strategy is to administer universal antifungal prophylaxis. Precise threshold
PPV and NPV will need to be clarified in prospective clinical trials. Studies also are needed on the
impact of antifungal treatment on non-culture test performance, which will have implications for
prophylaxis strategies.
5.2. Treating Individual Patients
The use of non-culture tests in caring for individuals is more nuanced than when screening
populations. Bayesian reasoning demands that any result be interpreted in some prior context [41,42].
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In a given patient, “context” encompasses factors such as presenting complaints, underlying conditions,
medications, physical findings, imaging studies and laboratory data, and the likelihood or exclusion
of alternative etiologies. Each factor is a “result” that carries its own likelihood ratio and adjusts the
probability of invasive candidiasis [41]. Even if each result has a low likelihood ratio, cumulatively
they achieve a more powerful effect equal to the product of individual ratios. Therefore, moderate-risk
ICU patients identified by clinical predictive scores (Mycoses Study Group criteria, as an example)
may have very different pre-test likelihoods of candidemia at the time of testing, even though scores by
themselves assign comparable risk (~10% incidence). The post-test likelihood may be further modified
by the magnitude of results; two highly positive results are more compelling than a single borderline
result. It is infeasible for clinicians to calculate precise running tallies of likelihood ratios in each
patient. Nevertheless, they can conceptualize pre-test and post-test probabilities qualitatively [41].
Examples of useful qualitative evaluations include “my patient is reasonably likely to have invasive
candidiasis, and a positive result significantly increases that likelihood”, or “in this low-risk patient,
a positive result does not help me, but a negative result essentially excludes the disease”.
Pre-test likelihood windows that are important when screening populations are less relevant in an
individual patient. A positive non-culture result with predictive value below a threshold nevertheless
may justify antifungal treatment of a sick patient if there is no alternative diagnosis. Likewise, there is
often clinical value in excluding invasive candidiasis, even if the pre-test likelihood is not within the
screening window.
6. Conclusions
The interpretive framework and management strategies proposed here must be validated in
clinical trials that assess endpoints such as rates of disease, patient outcomes, antifungal usage
and resistance, and economic costs. Much-needed T2Candida data will be available soon from a
multi-center study of patients with candidemia. In designing future trials of T2Candida, Fungitell
or other assays, particular attention should be paid to blood culture-negative, intra-abdominal or
deep-seated candidiasis. In addition, greater insight is needed into the optimal timing and frequency
of testing in various populations, impact of prior or ongoing antifungal therapy, and assay kinetics in
response to antifungal treatment. In the longer term, there is need for multi-plex assays, capable of
detecting Candida, other pathogens, and markers for drug resistance such as FKS gene mutations [4,43].
In the era of molecular medicine, infectious diseases practitioners increasingly will be called upon
to think and practice as Bayesians. In this regard, the diagnosis of invasive candidiasis is a case study
for the types of challenges that will be encountered more widely in the not-so-distant future.
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